Infectious Diseases News and Research

RSS

Tropical Infectious Disease Consortium wins £1.6m additional funding to support early-stage translational research

A new consortium involving the London School of Hygiene & Tropical Medicine (LSHTM) has launched to enhance the research to speed up development of real-world diagnostics and treatments, funded by UK Research and Innovation Medical Research Council (UKRI MRC).

4 Jul 2022

The importance of smallpox vaccination as a preventive measure in controlling recent outbreaks of monkeypox

Scientists have described the importance of smallpox vaccination as a preventive measure in controlling recent outbreaks of monkeypox infection.

4 Jul 2022

Discussing tools and resources to support the bladder cancer patient community

In this interview, Dr. Ignacio Durán and Alex Filicevas discuss key challenges and opportunities in the bladder cancer disease landscape and the future of care. This episode focuses on the bladder cancer patient support landscape, including a review of the tools and resources available to the community, as well as key unmet needs to address.

From Janssen Pharmaceuticals 4 Jul 2022

Understanding the impact of bladder cancer on daily life before and after diagnosis

In this interview, Dr. Ignacio Durán and Alex Filicevas, discuss key challenges and opportunities in the bladder cancer disease landscape and the future of care. They focus on the quality of life for patients and delve into the impact bladder cancer has on daily life, both before and after diagnosis and treatment, from the holistic perspective of both patients and HCPs.

From Janssen Pharmaceuticals 4 Jul 2022

Study: Patient's symptoms in current UK monkeypox cases differ from previous outbreaks

The first study on cases in the current UK monkeypox outbreak reports important differences in patient's symptoms to those observed in previous outbreaks elsewhere in the world.

1 Jul 2022

Nomogram helps predict anal cancer risk in HIV patients

Both cervical and anal cancer are caused by human papillomavirus. Both diseases also share a common precursor: abnormal cells known as high-grade squamous intraepithelial lesions (HSIL).

1 Jul 2022

Most therapeutic antibodies for treating COVID-19 patients do not inhibit emerging Omicron subvariants

The Omicron subvariants BA.1 and BA.2 of SARS-CoV-2 have dominated the COVID-19 pandemic in early 2022. In many countries, these viruses are now outcompeted by emerging subvariants, with BA.5 being responsible for the current uptick of cases in Germany.

1 Jul 2022

New antibody-based method for SARS-CoV-2 detection does not require a blood sample

Despite significant and stunning advances in vaccine technology, the COVID-19 global pandemic is not over. A key challenge in limiting the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is identifying infected individuals.

1 Jul 2022

HIV accelerates epigenetic aging soon after initial HIV infection

HIV has an "early and substantial" impact on aging in infected people, accelerating biological changes in the body associated with normal aging within just two to three years of infection, according to a study by UCLA researchers and colleagues.

1 Jul 2022

Stopping a pervasive bacterium that makes millions sick each year

As we head outdoors this summer, scientists are working to clip the long, flexible appendages that enable the common bacterium Campylobacter jejuni to make its way from undercooked poultry and natural waterways into our intestinal tract where it makes millions of us sick each year.

1 Jul 2022

Omicron subvariants BA.2.12.1, BA.4, and BA.5 show higher neutralization resistance to antibodies

In a recent study published in The Lancet Infectious Diseases, researchers investigated the neutralization sensitivity of the emerging Omicron sub-variants, BA.2.12.1, BA.4, and BA.5.

30 Jun 2022

Novel universal flu vaccine confers protection against different strains and subtypes of influenza A viruses

A new universal flu vaccine constructed with key parts of the influenza virus offers broad cross protection against different strains and subtypes of influenza A viruses in young and aged populations, according to a new study by researchers in the Institute for Biomedical Sciences at Georgia State University.

30 Jun 2022

Anticancer drug candidate that targets a human protein could be a pan-viral medication

More than two years into the COVID-19 pandemic, people are realizing that the "new normal" will probably involve learning to co-exist with SARS-CoV-2. Some treatments are available, but with new variants emerging, researchers are looking toward new strategies.

29 Jun 2022

Acute COVID-19 and vaccination induce cross-reactive antibody responses in breast milk

IgA and IgG in human breast milk and blood were assessed for their activity against SARS-CoV-2 and SARS-CoV-1, as well as four other prevalent HCoVs.

28 Jun 2022

UMass Amherst assistant professor wins $1.4 million grant to engineer synthetic bacteria for water contaminant removal

Lauren Andrews, University of Massachusetts Amherst assistant professor and the Marvin and Eva Schlanger Faculty Fellow in the department of chemical engineering, has received a three-year, $1.4 million grant from the National Science Foundation for a collaborative project to engineer synthetic bacteria to neutralize toxic contaminants found in drinking water.

28 Jun 2022

Phase 1 clinical trial of new influenza vaccine begins at NIH Clinical Center in Bethesda

A Phase 1 clinical trial of a novel influenza vaccine has begun inoculating healthy adult volunteers at the National Institutes of Health Clinical Center in Bethesda, Maryland.

28 Jun 2022

Low rates of severe COVID-19 found in patients treated with monoclonal antibodies during delta surge

A study of 10,775 high-risk adult patients during the COVID-19 delta variant surge in late 2021 finds that treatment with one of three anti-spike neutralizing monoclonal antibodies for mild to moderate symptoms led to low rates of severe disease, hospitalization, ICU admission and mortality, according to Mayo Clinic researchers.

28 Jun 2022

SARS-CoV-2 virus undertakes a massive takeover of the body's fat-processing system

The virus that causes COVID-19 undertakes a massive takeover of the body's fat-processing system, creating cellular storehouses of fat that empower the virus to hijack the body's molecular machinery and cause disease.

28 Jun 2022

Infectious period in healthy, vaccinated adults with SARS-CoV-2 is limited, study finds

In January 2022, the U.S. shifted its guidelines to recommend isolation of five days from COVID-19 symptom onset, followed by an additional five days of mask wearing.

27 Jun 2022

Rensselaer scientists secure $3.5 million grant to develop a low-dose, oral COVID antiviral drug

Rensselaer Polytechnic Institute researchers Gaetano Montelione and Christopher Cioffi will use a five-year, $3.5 million grant from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to develop a low-dose, oral COVID antiviral drug that can be administered at home.

27 Jun 2022

Infectious Diseases News and Research

Tropical Infectious Disease Consortium wins £1.6m additional funding to support early-stage translational research

The importance of smallpox vaccination as a preventive measure in controlling recent outbreaks of monkeypox

Discussing tools and resources to support the bladder cancer patient community

Understanding the impact of bladder cancer on daily life before and after diagnosis

Study: Patient's symptoms in current UK monkeypox cases differ from previous outbreaks

Nomogram helps predict anal cancer risk in HIV patients

Most therapeutic antibodies for treating COVID-19 patients do not inhibit emerging Omicron subvariants

New antibody-based method for SARS-CoV-2 detection does not require a blood sample

HIV accelerates epigenetic aging soon after initial HIV infection

Stopping a pervasive bacterium that makes millions sick each year

Omicron subvariants BA.2.12.1, BA.4, and BA.5 show higher neutralization resistance to antibodies

Novel universal flu vaccine confers protection against different strains and subtypes of influenza A viruses

Anticancer drug candidate that targets a human protein could be a pan-viral medication

Acute COVID-19 and vaccination induce cross-reactive antibody responses in breast milk

UMass Amherst assistant professor wins $1.4 million grant to engineer synthetic bacteria for water contaminant removal

Phase 1 clinical trial of new influenza vaccine begins at NIH Clinical Center in Bethesda

Low rates of severe COVID-19 found in patients treated with monoclonal antibodies during delta surge

SARS-CoV-2 virus undertakes a massive takeover of the body's fat-processing system

Infectious period in healthy, vaccinated adults with SARS-CoV-2 is limited, study finds

Rensselaer scientists secure $3.5 million grant to develop a low-dose, oral COVID antiviral drug

Industry Focus eBook - Infectious Diseases (3rd Edition) eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News